fenoTRACK operates as a non-invasive breath test that quantifies type 2 airway inflammation by measuring fractional exhaled nitric oxide (FeNO). Credit: myBiometry / Business Wire.

myBiometry has secured a $5m investment in an oversubscribed seed funding round to propel the development of its fenoTRACK device for asthma and chronic obstructive pulmonary disease (COPD).

The funding round was spearheaded by Dexcom Ventures and saw contributions from Elevate Ventures and CareSource Indiana, among other investor groups.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This financial boost is set to advance the fenoTRACK technology, a portable device that aims to empower patients with critical data for the early detection of exacerbations.

fenoTRACK operates as a non-invasive breath test that quantifies type 2 airway inflammation by measuring fractional exhaled nitric oxide (FeNO).

Type 2 inflammation is identified as a primary cause in 80% of asthma cases and 30%-40% of COPD cases.

The data obtained from FeNO measurements are crucial in identifying patients at heightened risk of an exacerbation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, personalising treatment based on FeNO data can diminish the risk of exacerbations by 38%-50% in adults and children, respectively.

myBiometry CEO Bryan Nolan said: “We’re excited to partner with Dexcom Ventures and CareSource as we near the milestone of submitting fenoTRACK for regulatory clearance.

“With enhanced at-home monitoring for asthma and COPD, we strive to identify attack risks sooner, enabling clinicians to offer more personalised care and preventive interventions that lessen the burden on patients, caregivers, and healthcare payers.”

CareSource Midwest regional vice-president Steve Smitherman said: “The impact of asthma and other lung diseases on the health and wellbeing of our members of all ages cannot be overstated.

“CareSource is constantly looking for innovations that can help our members better manage chronic conditions, which is why we are enthusiastic about Biometry’s work and a proud investor.”

The company is currently channelling its efforts towards finalising the development of the device and is also preparing for its regulatory submission.